Life Science Success

Send us a textMichael Papadimitrious is the Medical Affairs Manager for Miltenyi Biomedicine.  In this episode, Michael and I have a fantastic conversation about CAR-T therapy, delivering personalized cancer therapy and what the future may hold as science continues to evolve. 

Send us a textIn this podcast, I interview Gary McAuslan who has a consulting company GMAC Pharma that has been helping companies with their drug pipelines and commercialization activities. Additionally, Gary has now started ATGC Ventures a CDMO in Ireland. We cover Gary's history in pharma, how lean and an agile approach can help pharma companies and the key role that CDMO's will play in speeding drugs to market.

Send us a textIn this podcast, I interview Norris Turner the Principal for Turner Healthcare Quality Consulting.   We have a great discussion about his career, healthcare economic disparities, and his work with organizations around building a market access strategy and a healthcare quality strategy for their organizations and products.  Norris has also published some great blog posts that challenge existing thinking and provide some key insights on future improvements in healthcare systems.  

Send us a textToday I interview Michael Fero the Founder and President of TeselaGen. Michael and the team at TeselaGen have created an AI enabled operating system that can help biopharma companies design their next drug.  TeselaGen uses methods from machine learning and synthetic biology to help Pharmaceutical companies build and optimize cancer fighting drugs and vaccines by letting experimental data drive the discovery process.

Send us a textIn this episode, we discuss Ray's background in business development for three different companies.  Ray has spent time in Japan and in France working for a couple of different organizations.  Additionally, he completed his MBA in France.  Ray's employer, Phenovista is doing some interesting imaging work for their clients who are working on Phenotyping samples for assay development.

Send us a textIn this episode, I interview Janik Jaskolski CEO and product architect of Semalytix a company with an AI-driven way to gather patient insights about the treatments they are receiving. Semalytix is working with pharma companies to gather real-world evidence about patient experiences, outcomes, burdens, and needs.

Send us a textIn this episode, I interview Ken Banta Founder and Principal of the Vanguard Group. Ken has distinctly worked in the Life Sciences Industry with Pharmacia & Upjohn and Schering-Plough. He continues to work with CEO's and teams growing capabilities and changing the landscape for leadership in healthcare and life sciences. We dive into the shifts he has seen over the past year in delivery methods for his content as well as some key topics from his Harvard Business Review articles.

Send us a textIn this episode, I discuss with Patrina her career journey from Microscopy to Medical Affairs. She describes the contemplation of her early career choices leading to something that she loves with the Medical Affairs team at MedEvoke. At MedEvoke Patrina is working with companies on everything from conference posters through ensuring that critical communication methods are used in translating ideas within an organization. Additionally, in this podcast, we discuss a bit about where our paths crossed at GE and the hiking group at GE's API business in Issaquah WA had a hiking group that continued to flourish even after my time with the organization.

Send us a textJulio is the CEO of Bioaccesss (https://www.bioaccessla.com/) a CRO that focuses on transferring Life Science and Medical Device technologies into Latin America. Julio also hosts the LATAM Med Tech Leaders podcast and has written for Med Device Online. In this interview, we discuss trends in Latin America, the impact of COVID on his business and how his organization has had to think differently in our “new normal” to overcome the challenges.

Send us a textCarlos is the Founder of Lacerta Bio, Lacerta Bio is a pharmaceutical business development consultancy. We work with pharmaceutical, biotechnology, medical device, diagnostic, and other life science companies. We also work with venture capital and private equity firms that invest in these companies. He is also the CEO of Connexin Therapeutics, Inc. an early-stage glaucoma drug developer. Who has the goal of developing and partner novel connexin inhibitors for retinal neuroprotection secondary to glaucoma and other ophthalmic disease conditions. In this episode, we discuss his startup Connexin Therapeutics and how things are progressing for a startup that is focused on bringing a Glaucoma drug to market.